Aizant Drug Research Solutions Pvt. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aizant Drug Research Solutions Pvt. Ltd. - overview
Established
2005
Location
Hyderabad, -, India
Primary Industry
Pharmaceuticals
About
Aizant Drug Research Solutions Pvt. Ltd. is a Hyderabad-based company specializing in integrated drug development and pharmaceutical solutions, offering a range of services from R&D to clinical research and manufacturing. Founded in 2005 in Hyderabad, India, Aizant Drug Research Solutions Pvt.
Ltd. focuses on providing comprehensive drug development services. The company has completed a total of 3 deals. In the latest funding round in 2023, Aizant raised INR 601.
950 mn, bringing the total amount raised to INR 601. 950 mn and achieving a current company valuation of INR 4006. 377 mn. The CEO, Varma Rudraraju, has an extensive background in the pharmaceutical industry.
Aizant Drug Research Solutions Pvt. Ltd. specializes in providing integrated drug development and pharmaceutical solutions, including Research and Development (R&D), Contract Development and Manufacturing (CDMO), Contract Manufacturing Organization (CMO), and Clinical Research Organization (CRO) services. Their offerings include formulation development, analytical testing, clinical trial management, and scalable manufacturing, addressing the needs of pharmaceutical clients in various therapeutic areas such as cardiovascular, anticancer, antidiabetic, and antiviral drugs, with markets in the United States, Canada, Europe, and beyond.
In 2023, Aizant's revenue amounted to INR 23,825,251, with an EBITDA of INR 5,789,409. 5. The company operates through B2B transactions, engaging pharmaceutical and biotechnology firms for services like pre-formulation studies and commercial manufacturing under structured contracts designed to meet specific project needs, while ensuring regulatory compliance in product delivery. Aizant Drug Research Solutions Pvt.
Ltd. aims to leverage its recent funding of INR 601. 950 mn to enhance its service offerings and expand into new geographical markets. The company is focusing on developing new products tailored for the evolving pharmaceutical landscape and is targeting expansion into North America and Europe by 2025.
Invascent Capital Partners acquired Aizant, with financial details of the deal remaining undisclosed, which is likely to further support Aizant's strategic growth initiatives.
Current Investors
InvAscent Capital Partners, Zephyr Management
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare, Pharmaceuticals
Website
www.aizant.com
Total Amount Raised
Subscriber access only
Aizant Drug Research Solutions Pvt. Ltd. - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 444,466,000 | 616,143,000 | 755,694,000 | 756,035,000 | 1,078,493,000 | 1,082,764,000 | 1,503,267,000 | 1,438,570,000 | 1,322,282,000 | - | - | - |
| % Revenue Growth (YoY) | - | 38.6% | 22.6% | 0.0% | 42.7% | 0.4% | 38.8% | (4.3%) | (8.1%) | - | - | - |
| EBITDA (USD) | 181,305,000 | 277,111,000 | 131,130,000 | 123,664,000 | 218,598,000 | (157,723,000) | 200,320,000 | 109,493,000 | 97,771,000 | - | - | - |
| Operating Income (USD) | 160,528,000 | 245,921,000 | 83,463,000 | 81,447,000 | 170,123,000 | (235,179,000) | 103,548,000 | 6,211,000 | (6,566,000) | - | - | - |
| Operating Margin | 36.1% | 39.9% | 11.0% | 10.8% | 15.8% | (21.7%) | 6.9% | 0.4% | (0.5%) | - | - | - |
| % EBITDA Margin | 40.8% | 45.0% | 17.4% | 16.4% | 20.3% | (14.6%) | 13.3% | 7.6% | 7.4% | - | - | - |
| NET Income (USD) | 90,450,000 | 148,251,000 | 51,540,000 | 41,804,000 | 63,198,000 | (283,757,000) | 143,359,000 | (10,873,000) | (19,850,000) | - | - | - |
| % Net Margin | 20.4% | 24.1% | 6.8% | 5.5% | 5.9% | (26.2%) | 9.5% | (0.8%) | (1.5%) | - | - | - |
Aizant Drug Research Solutions Pvt. Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Aizant Drug Research Solutions Pvt. Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.